Home
For Healthcare Professionals
Healthcare Professional Home
Precision Medicine for Obesity
Clinical Studies
For Patients
Patient Home
What is Obesity Phenotyping
The Four Types of Obesity
Hungry Gut
Emotional Hunger
Slow Burn
How Our Test Works
About
Our Story
Leadership Team
Dr. Acosta Bio
Mark Bagnall Bio
Liv Williamsen Bio
Ross Higgins Bio
Media/Press
May 25 2022
October 5, 2022
February 14, 2023
March 28, 2023
March 30, 2023
DDW Precision Medicine Sessions 2023
June 23, 2023
June 28, 2023
July 19, 2023
August 4, 2023 WSJ
September 3, 2023 Pharma Voice
First Patent for Using Precision Medicine and Phenotyping to Treat Obesity
Obesity Week 2023 Hungry Brain Biomarker
Nature Study Press Release - 14 Mar 2024
Emotional Hunger Test Launch
$7.8M Funding Raise
Study Demonstrates MyPhenomeTM Hungry Gut Test Identifies Responders to Semaglutide
Hello Alpha - Phenomix Partnership Launch
TIME publishes MyPhenome test predicts response to Semaglutide
Consumer Survey Results Aug 1 2024
Phenomix Sciences and InformedDNA Partner to Advance Genetics-Driven Obesity Care
TIME Best Invention Award 2024
5 INTERESTNG COMPANIES I SAW AT HLTH
MyPhenome Test Shows Promise in Predicting Weight Gain, Highlighting Need for Early Intervention in Obesity
Duly Health Brings Genetic-Based Weight Loss Treatment to Chicago with MyPhenome Test
Phenomix Sciences Announces First Prospective Clinical Study of Semaglutide Using MyPhenome™ Test
Phenomix Sciences and Mayo Clinic to Present Landmark Research at DDW 2025, Advancing Precision Obesity Medicine
Mayo Clinic Study Shows MyPhenome Test Predicts GLP-1 Side Effects, Advancing Personalized Obesity Care and Drug Development
New Mayo Clinic Studies Find MyPhenome Test Predicts Recurrent Weight Regain After Bariatric Surgery
Phenomix and Mayo Clinic Publish Research Demonstrating Utility of MyPhenome Test for Personalized GLP-1 and Phen-Top Treatment
Partnerships
PRECISION MEDICINE IN OBESITY: APPLYING ONCOLOGY’S LESSONS TO TRANSFORM DRUG DISCOVERY AND DEVELOPMENT
Contact
